Talazoparib Oral Capsule
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
BRCA1 Mutation
Conditions
BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer, Fallopian Tube Cancer, High Grade Serous Carcinoma
Trial Timeline
Mar 29, 2021 → Dec 6, 2022
NCT ID
NCT04598321About Talazoparib Oral Capsule
Talazoparib Oral Capsule is a phase 1 stage product being developed by Pfizer for BRCA1 Mutation. The current trial status is terminated. This product is registered under clinical trial identifier NCT04598321. Target conditions include BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04598321 | Phase 1 | Terminated |
Competing Products
3 competing products in BRCA1 Mutation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Durvalumab + Olaparib + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Olaparib + Olaparib + Placebo + Placebo | AstraZeneca | Phase 3 | 77 |
| INO-5401 + INO-9012 | Inovio Pharmaceuticals | Phase 1 | 25 |